The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are: Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ. Participants will: Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Neurocognition
Timeframe: four weeks
Neurodegenerative disease panel
Timeframe: four weeks
Markers of systemic inflammation
Timeframe: four weeks